WOODBRIDGE, Conn. – ChemWerth, a leading supplier of generic active pharmaceutical ingredients (APIs), today announced the appointment of Tim Aust, M.D., to its Board of Directors. Dr. Aust succeeds Randy Wingate, who is stepping down after years of dedicated service. ChemWerth thanks Randy Wingate for his service and contributions to the Board and wishes him success in his future endeavors.
Dr. Aust currently serves as a hospitalist with BayCare Medical Group at Morton Plant Hospital in Clearwater, Florida. He previously worked as a hospitalist with the University of South Florida–Tampa General Hospital and as an Associate Professor, bringing a strong clinical and academic background to his role.
Prior to his medical career, Dr. Aust was Director of Operations at ChemWerth China, where he established and led a startup operation in Shanghai, overseeing P&L, sales strategy, vendor negotiations, and supply chain planning.
His experience as a practicing physician provides valuable insight into the end-user side of the generic pharmaceutical industry, complementing his prior experience on the development and operational side. Together, these perspectives strengthen his ability to contribute meaningfully to ChemWerth’s strategic direction. He also brings experience working with pharmaceutical manufacturers and suppliers globally.
“Tim brings a well-rounded perspective to the Board, combining firsthand medical experience with a deep understanding of the generic pharmaceutical supply chain,” said Peter Werth, Chairman of the Board of Directors. “His familiarity with our operations in both the United States and China, along with his insight into market dynamics, will be invaluable.”
Dr. Aust holds a Doctor of Medicine degree in Biomedical Sciences from the University of South Florida College of Medicine, along with degrees in Biomedical Physics and Multinational Business Operations. He also completed postgraduate studies in Mandarin Chinese in Taipei, Taiwan.
“I am honored to join the ChemWerth Board of Directors and contribute to the company’s continued growth,” said Dr. Aust. “Having been part of the organization earlier in my career, I look forward to bringing both my clinical perspective and operational experience to help guide its future direction.”
About ChemWerth: Established in 1982, ChemWerth is a full-service active pharmaceutical ingredient (API) development and supply company providing cGMP-quality APIs to regulated markets worldwide. ChemWerth is a global company headquartered in the United States, with offices in China and India. For more information, please visit www.chemwerth.com.
